Navigation Links
Cardium Completes $6.0 Million Registered Direct Offering
Date:10/20/2009

utic products for tissue repair and cardiovascular indications. In October 2009, Cardium announced results for the Matrix Phase 2b clinical study of the Excellarate product candidate as a treatment for patients with non-healing diabetic ulcers. News from Cardium is located at www.cardiumthx.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward-looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that the MATRIX study or other human clinical trials can be conducted and completed in an efficient and successful manner, that product formulation enhancements will be successful or will effectively simplify or expand the use of product candidates or technologies, that the GAM technology can be successfully broadened or applied to additional wound healing or tissue repair opportunities, that Excellarate or our other candidates will prove to be sufficiently safe and effective, that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures, that clinical studies even if successful will lead to product advancement or partnering, that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive, that FDA or other regulatory clearances or other certifications, or other commercialization efforts will be successful or will effectively enhance our businesses or their market value, that our products or product candidates will prove to be sufficiently safe and effective after introduction into a broader patient population, or that third parties on whom we depend will perform as anticipated.

Actual results
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors
2. Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications
3. Cardium Regains Listing Compliance with NYSE Amex
4. Cardiums InnerCool Therapies Business to Be Acquired By Royal Philips Electronics
5. Cardium Announces Conference Call and Webcast to Review Recent Developments and Future Plans for the Excellarate(TM) Clinical Development Program
6. FDA has Granted HUD (Humanitarian Use Device) Designation to ITGIs Pericardium Covered Stents, Over and Under(R) and Aneugraft(R), for Treatment of Perforations and Dissections of Native Coronary Arteries and Saphenous Vein Grafts
7. Cardium Completes $3.5 Million Credit Facility
8. Cardium Announces Retirement of Director
9. Cardiums InnerCool Announces First Patient Treated With New Tissue-Specific UroCool(TM) System in Robotic-Assisted Prostate Surgery Study
10. Cardiums InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries
11. Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... MX (PRWEB) September 18, 2014 September ... Mexico City, MX. ASEA is the manufacturer of the ... the skin care product, RENU28. , The Mexico ... Vice President Duvan Botero, and ASEA Field Leader Shawn ... holds a PhD in Atomic/Medical Physics from the University ...
(Date:9/17/2014)... - Oncothyreon Inc. (NASDAQ: ONTY ) today ... of its Common Stock and Series A Convertible Preferred ... Series A Convertible Preferred Stock is non-voting and convertible ... will be prohibited if, as a result, the holder ... of the Common Stock then outstanding. As part of ...
(Date:9/17/2014)... September 17, 2014 A biodegradable ... microorganisms such as bacteria, fungi, and algae into ... methane, biomass, inorganic compounds, carbon dioxide, and humus ... customer base and improved costs, biodegradable polymers are ... viable alternative to conventional polymers. Primary factors that ...
(Date:9/17/2014)... Intarcia Therapeutics, Inc. today announced the presentation ... cost and predictability of non-adherence in type 2 diabetes ... the European Association for the Study of Diabetes (EASD). ... Ph.D., of Analysis Group, Inc. presented data from the ... to characterize the prevalence of non-adherence and serial non-adherence, ...
Breaking Biology Technology:Announcing the ASEA Mexico Grand Opening Tour Beginning September 18th 2Oncothyreon Announces Proposed Public Offerings 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5
... Receive Funding, From Allied Minds to Commercialize Novel Technology for the ... ... Aliquots, BOSTON, July 2 Allied Minds, a pre-seed investment,corporation ... Development, and Northeastern,University announce the creation of CryoXtract Instruments, LLC, a ...
... levels as a possible ... predictor of clinical activity -, TORONTO, ... ("Lorus" or the "Corporation"), a biopharmaceutical company,specializing in the research ... cancer, today announced publication by,an Ohio State University (OSU) clinical ...
... Microfluidic Systems Inc.,(MFSI) announced today that it has ... of Microfluidic - Bioagent Autonomous Networked Detector,(M-BAND). This ... funded phases by the DHS,Science and Technology Directorate ... allow for low-volume production of automated,systems for extended ...
Cached Biology Technology:Investment Firm Allied Minds to Commercialize New Frozen Aliquotter Technology with Two Local Major Universities. 2Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 2Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 3Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 4Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 5Microfluidic Systems Receives Continued Funding From the Department of Homeland Security (DHS) Toward the Commercial Production of Autonomous Airborne Pathogen Detection Systems 2Microfluidic Systems Receives Continued Funding From the Department of Homeland Security (DHS) Toward the Commercial Production of Autonomous Airborne Pathogen Detection Systems 3
(Date:9/17/2014)... 2014) A rare genetic disorder known as Jacobsen syndrome ... joint investigation by researchers at San Diego State University ... to suggesting better treatment options for people with Jacobsen ... genetic underpinnings of autism., Jacobsen syndrome affects approximately 1 ... Health. It occurs in a person when there is ...
(Date:9/17/2014)... Evolution and Yale University offers compelling support for the ... partially predict the likelihood of being diagnosed with mental ... life. The study analyzed medical records of 1.75 million ... 30 years, and adjusted for almost all other known ... Proceedings of the Royal Society, London B . ...
(Date:9/17/2014)... the Catalan Institute of Oncology-Bellvitge Biomedical Research Institute ... genes differentially expressed in normal accompanying cells in ... used to classify colorectal tumors, predict the evolution ... decisions to prevent relapses. , Biomarkers ... in our population considering both sexes. About 30,000 ...
Breaking Biology News(10 mins):A link between Jacobsen syndrome and autism 2Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Five genes to predict colorectal cancer relapses 2
... saying goes: "Don,t judge a book by its cover." Well, ... dolphins are the most common and well-known of their kind ... dolphin might look similar to another, when you take a ... are differences. In fact, a recently published study in the ...
... Institute for Clinical Research, Inc., a company providing science-driven early ... appointment of Dan Bradbury , Managing Member of ... Board of Directors.  Mr. Bradbury joins Profil Institute,s current ... research executive and former Senior Vice President and Head ...
... cats really had nine lives, one reason might be to ... feline health. Yunjeong Kim, a research assistant professor in ... developed a research approach that tackles two deadly infectious feline ... by a $156,342 award from the Morris Animal Foundation. ...
Cached Biology News:Dolphin genetic study provides revelations 2Profil Institute Appoints Dan Bradbury, former Amylin Pharmaceutical CEO, to Board of Directors 2Profil Institute Appoints Dan Bradbury, former Amylin Pharmaceutical CEO, to Board of Directors 3College of Veterinary Medicine researcher doubles down on deadly, infectious cat diseases 2College of Veterinary Medicine researcher doubles down on deadly, infectious cat diseases 3
... Kit is designed for concentration and ... samples. Proteomics sample analysis is often ... impurities such as buffers, salts and ... interfere with electrophoretic separations or enzymatic ...
... activated carrier proteins to simplify the ... Activated Carrier Proteins are commonly used ... a heterobifunctional cross-linker (Sulfo-SMCC). This activation ... protein. Thus allowing the maleimide-activated ...
... allows for rapid, convenient, and efficient native ... process utilizes a spin column to make ... concentration of proteins which were electro-eluted in ... ion exchangers, offering high binding capacity fo ...
... clear polystyrene with frosted labeling surfaces, ... cell counting. 100% integrity tested. Linkage: ... product number, created to easily match ... availability yet, please order under the ...
Biology Products: